GET DAILY SIGNALSHarvard Bioscience (HBIO) Q3 Earnings: Revenue Rises 8% With Mixed Margin Signals
Key Takeaways
- Revenue rose 8% year over year to $22.2 million, marking a second straight quarter of solid top-line growth.
- Adjusted EPS (earnings per share) came in at -$0.06, beating the consensus estimate of -$0.27, while revenue topped the $21.85 million estimate.
- GAAP (generally accepted accounting principles) net loss widened to $2.6 million, or $0.58 per share, from $1.2 million a year earlier.
- Adjusted gross margin compressed to 57.1% from 59.2%, pressured by a higher-mix of lower-margin CMT (Cellular & Molecular Technology) and distribution/China sales.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $1.8 million, down from $2.0 million in the prior-year quarter.
- Management reaffirmed full-year revenue growth of 3%–5% but trimmed its full-year adjusted EBITDA growth outlook to a range of -1% to +4%.
- For deeper context on this stock, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover automated market strategies and ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Harvard Bioscience is a life-sciences tools provider undergoing a deliberate transition toward translational and preclinical research technologies, including telemetry, electrophysiology, and organoid platforms. This quarterly report matters because it is the clearest test yet of whether the company's turnaround — built on cost discipline, commercial realignment, and its "Project Viking" manufacturing consolidation — can convert revenue growth into durable profitability. Investors are closely watching whether strengthening demand from CROs (contract research organizations) and China can offset persistent softness in academic and European markets, all while the company manages an elevated debt load and thin margins. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Harvard Bioscience reported third-quarter 2026 revenue of $22.2 million, up 8% from $20.6 million in the prior-year period and above the roughly $21.85 million consensus estimate. Adjusted EPS was -$0.06, significantly better than the -$0.27 analysts expected. On a GAAP basis, the company posted a net loss of $2.6 million, or $0.58 per share, compared with a loss of $1.2 million, or $0.28 per share, a year earlier.
GAAP gross margin was 55.4%, down from 58.4% last year, while adjusted gross margin slipped to 57.1% from 59.2%. Adjusted EBITDA declined to $1.8 million from $2.0 million. Geographically, Americas revenue grew 9% to $11.3 million, Asia-Pacific (APAC) revenue jumped 29% to $4.6 million — including a 31% gain in China — while Europe, the Middle East and Africa (EMEA) revenue fell 5% to $6.3 million amid weak academic demand. Cash used in operations through nine months was $0.6 million, versus $6.8 million generated a year earlier. From what I see, the geographic split highlights where growth is coming from right now.
Market Reaction and Investor Sentiment
Shares traded around $9.12 in premarket activity following the release, near the top of the stock's 52-week range of $4.00 to $9.32, after closing the prior session at $9.09. The initial reaction reflected relief that revenue and adjusted EPS both topped estimates, even as the results highlighted margin compression. Sentiment remains bifurcated: bulls point to accelerating top-line growth, a stronger backlog, and progress on Project Viking, while bears focus on declining gross margins, negative operating cash flow year to date, and a net-debt position of $35.1 million.
Forward Outlook and Key Factors to Monitor
For the fourth quarter, management guided revenue of $23.7 million to $25.5 million, adjusted gross margin of 59%–61%, and adjusted EBITDA of $3.8 million to $4.2 million. Full-year 2026 revenue growth was reaffirmed at 3%–5% with adjusted gross margin of 57%–59%, but the adjusted EBITDA growth target was revised down to a range of -1% to +4% to reflect a heavier mix of lower-margin CMT products and higher distribution and China sales.
Investors should monitor several key items in the coming quarters. First, the completion of Project Viking in the first quarter of 2027 is expected to deliver roughly $3 million in cost savings in 2027 and $4 million annually thereafter, a potential catalyst for margin and cash-flow recovery. Second, watch whether the company can place an asset-based revolving credit facility to reduce interest costs and improve working-capital flexibility.
Demand signals also remain important. CRO and China sales have driven recent growth, while academic funding in the U.S. and Europe remains sluggish; any improvement there could provide upside, though management is not baking that into guidance. Finally, investors should track cash generation and the net-debt balance closely, since these will determine the company's ability to fund operations and execute its turnaround without additional dilution. I’m watching this closely as the debt and cash metrics could shape the next phase.
Exploring Tickeron’s AI Tools
In my view, Tickeron’s AI Screener has become a useful part of my routine for scanning opportunities across sectors. It lets me apply filters for fundamentals, patterns, and AI signals to quickly surface ideas that align with the themes I’m following, such as life-sciences tools or turnaround stories. This approach helps me stay efficient without replacing my own analysis of earnings reports and guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HBIO in downward trend: price may drop because broke its higher Bollinger Band on November 09, 2026
HBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In 31 of the 36 cases the stock fell afterwards. This puts the odds of success at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 46 cases where HBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on HBIO as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for HBIO just turned positive on November 09, 2026. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in 40 of 53 cases over the following month. The odds of a continued upward trend are 75%.
Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in 162 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 81 of 108 cases where HBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.130) is normal, around the industry mean (4.964). P/E Ratio (-3.635) is within average values for comparable stocks, (40.591). HBIO's Projected Growth (PEG Ratio) (14.400) is slightly higher than the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of apparatus and scientific instruments
Industry PharmaceuticalsOther
Advertisement